Navi Mumbai Municipal Corporation, Covid-19 DCHC and ICU, Navi Mumbai.
J Assoc Physicians India. 2022 Apr;70(4):11-12.
Navi Mumbai Municipal Corporation, Covid-19 DCHC and ICU, Navi Mumbai COVID- 19 pandemic has become a leading cause of morbidity and mortality worldwide since the emergence of novel coronavirus SARS-CoV-2 in December 2019. The patterns of imaging abnormalities and data from prior coronavirus outbreaks suggest that patients with severe COVID-19pneumonia are at increased risk of progression to interstitial lung disease and chronic pulmonary vascular disease.We have devised an effective,inexpensive approach for Covid-19 recovering patients to reduce the incidence and severity of these pulmonary complications.
This cross sectional study was conducted across two centres-largest government-run DCHC,Vashi, Navi Mumbai and private tertiary care hospital in Airoli, Navi Mumbai from Nov'20 to Feb'21. IEC approval, consent was obtained.472 patients were enrolled. Demographic,clinical,radiological data was collected.Adults >18yrs who tested Covid-19 RTPCR/ Rapid Antigen Positive, HRCTSS of >10, required home oxygen of 4lts/min and above, ABG established hypoxia,oxygen saturation of 82% to 94%RA, with/without existing comorbidities were included in the study.Covid Rehabilitation Therapy included six alternate day OPD based sessions over twelve days starting three days after the day of discharge from the hospital.Each session included clinical assessment,15 minute intensive chest physiotherapy and breathing exercises followed by 6 minutes of nebulisation with Levosalbutamol+Ipratropium bromide and Budesonide,followed by high flow humidified oxygen therapy of 10lts/min via non breathable mask for 90 minutes along with breathing variation of inhalation:exhalation of 1:2. Oxygen Saturation, Pulse,BP, RR were established at the beginning of every session and the end of the session.6MWT,Chest Xray was obtained at first and sixth session.These factors were used to determine outcome measures in Covid Rehabilitation Therapy.
Of 472patients, 218(46.2%) were females, 254(53.8%) were males, 179(38%) had baseline saturation 82-85% on RA, 186(40%) had 85-90%, 107(22.6%) had 90-94% RA. 78% have improved to saturation of 98% at the end of last session of therapy,8%improved to 97%,10% to 96%,4% to 95%. 354(75%) patients showed 3/4th resolution of fibrosis on Chest Xray, 70(14.8%) showed 1/2 resolution,48(10.2%) have 1/4 resolution on CXR. 82% patients showed complete normalcy on 6MWT,15% showed partial improvement and 3% have showed no change.82% patients were able to come off home oxygen within 4 days,12% within 10 days and 6% within 21 days of completing therapy.369 patients reported significant reduction in dyspnea,chest pain.The results of therapy are remarkable and we had 0 defaulters.These patients as compared to the ones who didn't opt for the therapy did not have any complications after 1month on follow up versus those who presented with intermittent dyspnea and fatiguability after one month of Covid.
Covid-19 Rehabilitation Therapy is cost effective,easy and convenient approach to reduce and prevent related pulmonary complications and must be advocated.
Navi Mumbai 市政公司、Covid-19 DCHC 和 ICU,自 2019 年 12 月新型冠状病毒 SARS-CoV-2 出现以来,Covid-19 大流行已成为全球发病率和死亡率的主要原因。先前冠状病毒爆发的影像学异常模式和数据表明,严重 COVID-19 肺炎患者有进展为间质性肺病和慢性肺血管疾病的风险增加。我们已经设计了一种有效的、廉价的方法,用于 COVID-19 康复患者,以降低这些肺部并发症的发生率和严重程度。
这项横断面研究在 Navi Mumbai 的两个中心进行-最大的政府运营的 DCHC,Vashi 和 Navi Mumbai 的私人三级护理医院,从 2020 年 11 月至 2021 年 2 月。获得了 IEC 批准和同意。共纳入 472 名患者。收集了人口统计学、临床、放射学数据。纳入标准为:年龄>18 岁,新冠病毒 RT-PCR/快速抗原阳性,HRCTSS>10,需要 4 升/分钟以上的家庭氧气,ABG 确定缺氧,82%至 94%的 RA 血氧饱和度,伴有/不伴有现有合并症。COVID 康复治疗包括从医院出院后三天开始的十二天内六次隔日 OPD 基础治疗,每次治疗包括临床评估、15 分钟强化胸部物理治疗和呼吸练习,然后用沙丁胺醇+异丙托溴铵和布地奈德进行 6 分钟雾化,然后用非透气面罩进行 90 分钟的 10 升/分钟高流量湿化氧疗,同时进行吸入:呼气 1:2 的呼吸变化。在每次治疗的开始和结束时确定血氧饱和度、脉搏、血压、呼吸频率。在第一次和第六次治疗时获得 6MWT 和胸部 X 光片。这些因素用于确定 COVID 康复治疗的结果测量。
在 472 名患者中,218 名(46.2%)为女性,254 名(53.8%)为男性,179 名(38%)基线 RA 血氧饱和度为 82-85%,186 名(40%)为 85-90%,107 名(22.6%)为 90-94% RA。78%的患者在治疗的最后一次治疗结束时改善到饱和度为 98%,8%改善到 97%,10%改善到 96%,4%改善到 95%。354 名(75%)患者的胸部 X 光显示纤维化 3/4 消退,70 名(14.8%)显示 1/2 消退,48 名(10.2%)显示 1/4 消退。82%的患者在 6MWT 上显示完全正常,15%显示部分改善,3%显示无变化。82%的患者能够在 4 天内停止家庭吸氧,12%在 10 天内,6%在完成治疗后 21 天内。369 名患者报告呼吸困难和胸痛明显减轻。治疗结果显著,我们没有出现失访。与没有接受治疗的患者相比,这些患者在 1 个月的随访后没有任何并发症,而那些在 COVID 后一个月出现间歇性呼吸困难和疲劳的患者则有并发症。
COVID-19 康复治疗是一种经济有效的、简单方便的方法,可减少和预防相关的肺部并发症,必须得到提倡。